Pediatric ependymoma

Last updated

Pediatric ependymomas are similar in nature to the adult form of ependymoma in that they are thought to arise from radial glial cells lining the ventricular system. However, they differ from adult ependymomas in which genes and chromosomes are most often affected, the region of the brain they are most frequently found in, and the prognosis of the patients. Children with certain hereditary diseases, such as neurofibromatosis type II (NF2), have been found to be more frequently afflicted with this class of tumors, but a firm genetic link remains to be established. Symptoms associated with the development of pediatric ependymomas are varied, much like symptoms for a number of other pediatric brain tumors including vomiting, headache, irritability, lethargy, and changes in gait. Although younger children and children with invasive tumor types generally experience less favorable outcomes, total removal of the tumors is the most conspicuous prognostic factor for both survival and relapse.

Contents

Basic biology

Cell of origin

Ependymomas are believed to arise from radial glial cells. Tumorspheres derived from ependymomas display a radial-glial like phenotype, expressing neuronal stem cell markers CD133 and nestin, as well as radial glial specific markers RC2 and brain lipid binding protein (BLBP/FABP7). Tumorspheres with radial glial characteristics form tumors in orthotopic mouse xenografts, suggesting radial glial as cell of origin for ependymomas. [1] [2]

Inheritance

A number of genetic syndromes are associated with the development of ependymoma, including neurofibromatosis type II (NF2), Turcot syndrome B, and MEN1 syndrome. However, gene mutations linked to the familial syndromes are rarely found in sporadic cases of ependymoma. [3] For example, NF2 mutations have rarely been observed in ependymomas and MEN1 mutations have only been found in a small number of cases of ependymoma recurrences. [4] [5] [6] [7]

Oncogenic lesions

ERBB2 , ERBB4 , and human telomerase reverse transcriptase ( TERT ) gene expression promote tumor cell proliferation, contributing to aggressive tumor behavior. [8] [9] [10] High expression of epidermal growth factor receptor (EGFR) correlates with unfavorable outcome. [9] Over-expression of kinetochore proteins and down-regulation of metallothioneins are associated with recurrence in ependymomas. [11] KIT receptor tyrosine kinase and phospho-KIT were found to be present in pediatric ependymomas and may be involved in angiogenesis associated with those tumors. [12]

Chromosomal changes

Comparative genomic hybridization (CGH) experiments have shown pediatric ependymomas possess a number of genomic anomalies not seen in adult ependymomas. [13] In addition, ependymomas from different locations within the central nervous system (spinal, supratentorial, and infratentorial) can be distinguished by their chromosomal, immunohistochemical, and gene expression differences. [13]

Amplification of chromosome 1q and loss of 6q, 17p and 22q are the most common numerical chromosomal changes in pediatric ependymomas. [14] [15] [16] Gain of chromosome 1q (1q21.1-32.1) is more common in the pediatric population and is associated with tumor recurrence in intracranial ependymomas. Moreover, gain of chromosome 1q25 has been found to independent prognostic value for recurrence-free and overall survival. [9] Loss of 22q has been found in both sporadic and familial cases, supporting the presence of a tumor suppressor gene at this location. [17] [18] However, loss of 22q is more common in the adult form than pediatric cases. [14] [18] [19] As NF2 is located on 22q12.2, it was hypothesized to be involved in the development of ependymoma. Though mutations in NF2 are rarely found in sporadic ependymomas other than the spinal form, [4] [20] SCHIP1, a NF2 interacting gene, is significantly down-regulated in pediatric ependymomas, supporting a role for the NF2 pathway in the initiation of ependymomas. [21]

Oncogenes and tumor suppressor genes

A variety of oncogenes and tumor suppressor genes have been found to be mutated or possess altered expression in pediatric ependymomas. KIT receptor tyrosine kinase and phospho-KIT have been suggested to play a role in the development of pediatric ependymomas, [12] NOTCH1 mutations have been found in approximately 8% of pediatric ependymomas, [22] and MEN1 mutations are occasionally found in pediatric ependymomas. [23] MMP2 and MMP14 appear to also play a role in tumor growth and progression in intracranial cases. [24] Two candidate genes, TPR and CBY1 , have been identified on commonly altered chromosome regions in pediatric ependymomas, chromosomes 1q25 and chromosome 22q12-q13. [25] Expression of two additional candidate genes, S100A6 and S100A4 on chromosome 1q have also been found to correspond to supratentorial tumor development and tumors occurring before the age of 3 years old, though it is unclear exactly what role these genes play in the etiology. [26]

Tumor progression

Ependymomas have been suggested to arise from radial glial cells, suggesting neural stem cell maintenance pathways such as Notch, sonic hedgehog (SHH), and p53 are important for the pathogenesis of ependymomas. [1]

Notch signaling pathway and HOX family of transcription factors are up regulated in supratentorial and spinal ependymomas respectively. [1] Over-expression of Notch ligands, receptors, and target genes ( HES1 , HEY2 , and MYC ), as well as down-regulation of Notch repressor (FBXW7) are found in pediatric ependymoma. [22] Inhibition of Notch pathway impairs tumor growth in vitro . [22] Notch target ErbB2 is up-regulated in most ependymomas, correlating with poor outcome. [8]

While p53 ( TP53 ) mutations are not often observed in pediatric ependymoma, [27] the p53 pathway is suggested to play a role in radiation therapy resistance [28] and tumor progression, [29] possibly via over-expression of MDM2 . [30] Further, up-regulation of p73 ( TP73 ), a homolog of p53, and deletion of the p53 pathway gene p14arf/p16/INK4A (CDKN2A) have also been found in pediatric ependymomas. [3]

Over-expression of components of SHH pathway such as GLI1 , GLI2 , and STK36 implicates deregulation of the SHH pathway in ependymomas. [3] Moreover, over-expression of SHH targets IGFBP2 , IGFBP3 , and IGFBP5 in ependymoma is also suggestive of a role for SHH and insulin-like growth factor (IGF) signaling in the pathogenesis of pediatric ependymomas. [31]

Rate of progression

Endothelial cell KIT expression was associated with a young age at diagnosis of pilocytic astrocytoma or ependymoma. [12] Telomerase activity is found in childhood ependymoma. In addition, telomerase reactivation and maintenance of telomeres appears to be required for progression. Low expression of nucleolin, an interacting protein of telomerase, was found to be the single most important biological predictor of outcome, where low expression correlates with a more favorable prognosis. [32]

Clinical biology

Presentation

Symptoms present 1–36 months before diagnosis, and can vary depending on age, tumor grade, and location. Increased intracranial pressure can induce vomiting, headache, irritability, lethargy, changes in gait, and in children less than 2, feeding problems, involuntary eye movements, and hydrocephalus are often noticeable. Seizures occur in about 20% of pediatric patients. [33] [34] Loss of cognitive function and even sudden death could occur if the tumor is located at a crucial location for CSF flow. Pediatric ependymomas most often occur in the posterior cranial fossa, in contrast with adult ependymomas which usually occur along the spine. [35] Ependymomas present as low-density masses on CT scans, and are hyperintense on T2-weighted MRI images. [36]

Pathology

Significant debate remains over grading of ependymomas, [37] though the WHO 2007 classification lists subependymoma (grade I), myxopapillary ependymoma (grade I), ependymoma (grade II), and anaplastic ependymoma (grade III) as the primary classifications. [38] This classification scheme further designates four subtypes within the ependymoma group. However, there are several recognized subtypes of ependymoma with differing pathologies. These include myxopapillary ependymoma (MEPN) which tend to grow slowly and are restricted to the conus medullaris-cauda equina-filum terminale region of the spinal cord, intracranial, infratentorial (posterior fossa), intracranial supratentorial, and spinal ependymoma, and subependymomas. Reports have shown that location-based classification is most relevant to the molecular characteristics, implicating underlying tissue-specificity effects. [1]

Ependymomas arise from oncogenic events mutating normal ependymal cells into cancerous cells. Recent evidence suggests the primary cells are radial glia. Genetic alterations are fairly heterogeneous among histologically similar ependymoma tumors. [1]

Diagnostic features

Comparative genomic hybridization (CGH) experiments have shown pediatric tumors possess a number of genomic anomalies not seen in adult ependymomas, with a high prevalence of whole chromosome imbalances. [13] [39] Epithelial membrane antigen has been shown to help distinguish ependymomas from other pediatric CNS tumors. [40] Neuraxis MR imaging and lumbar CSF cytology evaluation are widely accepted methods for determining tumor dissemination. [41]

Differential diagnoses

Once a tumor is suspected, medulloblastomas, diffuse astrocytomas, pilocytic astrocytomas, and ependymomas remain in the differential diagnosis as posterior fossa tumors. However, only pilocytic astrocytomas and ependymomas stain positively for Galectin-3. [42] The subtype of ependymoma can also be narrowed down by molecular means. For instance, the myxopapillary ependyomas have been found to have higher expression of HOXB5 , PLA2G5 , and ITIH2 . [43] A gene expression profiling experiment has shown that three members of the SOX family of transcription factors also possessed discriminatory power between medulloblastomas and ependymomas. [44] Without histology, it is difficult to differentiate grade II versus grade III anaplastic ependymomas because there are no anatomical differences on magnetic resonance imaging. [45]

Prognostic features

In general, pediatric ependymomas are associated with less favorable prognoses than adult ependymomas, and ependymomas of younger pediatric patients are less favorable than ependymomas of older pediatric patients (reviewed in [35] ). Tumors that occur in the posterior fossa have also been shown to have a less favorable prognosis. [46] Expression of TERT in pediatric intracranial ependymomas is correlated with telomerase activity and tumor progression and negatively correlated with survival. [47] The protein nucleolin and expression of MMP2 and MMP14 have been found to inversely correlate with progression free survival in cases of pediatric ependymoma, though RTK-1 family members were not correlated. [24] [32] Tumor microinvasion, even in tumors appearing well-demarcated using various imaging modalities, was also found to be inversely associated with|progression-free and overall survival. [24] Some evidence suggests chromosome 6q25.3 deletion may provide additional survival benefit in pediatric ependymomas. [48]

Treatment

Chemotherapy regimens for pediatric ependymomas have produced only modest benefit and degree of resection remains the most conspicuous factor in recurrence and survival. [49] [50] [51] [52] [53]

The association of TERT expression with poor outcome in pediatric ependymomas has driven some researchers to suggest that telomerase inhibition may be an effective adjuvant therapy for pediatric ependymomas. Further, data from in vitro experiments using primary tumor isolate cells suggest that inhibition of telomerase activity may inhibit cell proliferation and increase sensitivity of cells to DNA damaging agents, [54] consistent with the observation of high telomerase activity in primary tumors. [32] Additionally, because apurinic/apyrimidinic endonuclease (APE1) has been found to confer radiation resistance in pediatric ependymomas, it has been suggested that inhibitors of Ap endo activity might also restore radiation sensitivity. [55]

Within the infratentorial group of pediatric ependymomas, radiotherapy was found to significantly increase 5-year survival. [56] However, a retrospective review of stereotactic radiosurgery showed it provided only a modest benefit to patients who had previously undergone resection and radiation. [57] Though other supratentorial tumors tend to have a better prognosis, supratentorial anaplastic ependymomas are the most aggressive ependymoma and neither total excision nor postoperative irradiation was found to be effective in preventing early recurrence. [58]

Following resection of infratentorial ependymomas, residual tumor is more likely in lateral versus medial tumors, classified radiologically pre-operatively. [59] [60] Specific techniques, such as cerebellomedullary fissure dissection have been proposed to aid in complete resection while avoiding iatrogenic effects in these cases. [60] Surveillance neuroimaging for recurrence provides additional survival to patients over observation alone. [61]

Biochemical markers

hTERT and yH2AX are crucial markers for prognosis and response to therapy. High hTERT and low yH2AX expression is associated with poor response to therapy. Patients with both high or low expression of these markers make up the moderate response groups. [62]

Relapse

The 5-year disease-free survival for age >5 years is 50-60%. [63] Another report found a similar 5-year survival at about 65% with 51% progression-free survival. [64] The 10-year disease-free survival is 40-50%. Younger ages showed lower 5 and 10-year survival rates. [63] A 2006 study that observed 133 patients found 31 (23.3%) had a recurrence of the disease within a five-year period. [62]

Long-term consequences of treatment

Use of telomerase inhibitors such as Imetelstat seem to have very low toxicity compared to other chemotherapy. The only known side effect of most telomerase inhibitors is dose-induced neutropenia. [65] Neuropsychological deficits can result from resection, [66] chemotherapy, [67] and radiation, as well as endocrinopathies. [68] Additionally, an increase in gastrointestinal complications has been observed in survivors of pediatric cancers. [69]

Related Research Articles

<span class="mw-page-title-main">Brain tumor</span> Neoplasm in the brain

A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors: malignant tumors and benign (non-cancerous) tumors. These can be further classified as primary tumors, which start within the brain, and secondary tumors, which most commonly have spread from tumors located outside the brain, known as brain metastasis tumors. All types of brain tumors may produce symptoms that vary depending on the size of the tumor and the part of the brain that is involved. Where symptoms exist, they may include headaches, seizures, problems with vision, vomiting and mental changes. Other symptoms may include difficulty walking, speaking, with sensations, or unconsciousness.

<span class="mw-page-title-main">Wilms' tumor</span> Rare childhood cancer of the kidneys

Wilms' tumor or Wilms tumor, also known as nephroblastoma, is a cancer of the kidneys that typically occurs in children, and occurs most commonly as a renal tumor in child patients. It is named after Max Wilms, the German surgeon (1867–1918) who first described it.

<span class="mw-page-title-main">Glioma</span> Tumour of the glial cells of the brain or spine

A glioma is a type of tumor that starts in the glial cells of the brain or the spine. Gliomas comprise about 30 percent of all brain tumors and central nervous system tumours, and 80 percent of all malignant brain tumours.

<span class="mw-page-title-main">Oligodendroglioma</span> Medical condition

Oligodendrogliomas are a type of glioma that are believed to originate from the oligodendrocytes of the brain or from a glial precursor cell. They occur primarily in adults but are also found in children.

<span class="mw-page-title-main">Ependymoma</span> Medical condition

An ependymoma is a tumor that arises from the ependyma, a tissue of the central nervous system. Usually, in pediatric cases the location is intracranial, while in adults it is spinal. The common location of intracranial ependymomas is the fourth ventricle. Rarely, ependymomas can occur in the pelvic cavity.

<span class="mw-page-title-main">Meningioma</span> Type of tumor

Meningioma, also known as meningeal tumor, is typically a slow-growing tumor that forms from the meninges, the membranous layers surrounding the brain and spinal cord. Symptoms depend on the location and occur as a result of the tumor pressing on nearby tissue. Many cases never produce symptoms. Occasionally seizures, dementia, trouble talking, vision problems, one sided weakness, or loss of bladder control may occur.

<span class="mw-page-title-main">Glioblastoma</span> Aggressive type of brain cancer

Glioblastoma, previously known as glioblastoma multiforme (GBM), is the most aggressive and most common type of cancer that originates in the brain, and has very poor prognosis for survival. Initial signs and symptoms of glioblastoma are nonspecific. They may include headaches, personality changes, nausea, and symptoms similar to those of a stroke. Symptoms often worsen rapidly and may progress to unconsciousness.

<span class="mw-page-title-main">Anaplastic large-cell lymphoma</span> Medical condition

Anaplastic large-cell lymphoma (ALCL) refers to a group of non-Hodgkin lymphomas in which aberrant T cells proliferate uncontrollably. Considered as a single entity, ALCL is the most common type of peripheral lymphoma and represents ~10% of all peripheral lymphomas in children. The incidence of ALCL is estimated to be 0.25 cases per 100,000 people in the United States of America. There are four distinct types of anaplastic large-cell lymphomas that on microscopic examination share certain key histopathological features and tumor marker proteins. However, the four types have very different clinical presentations, gene abnormalities, prognoses, and/or treatments.

<span class="mw-page-title-main">Neuroblastoma</span> Medical condition

Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently starts from one of the adrenal glands but can also develop in the head, neck, chest, abdomen, or spine. Symptoms may include bone pain, a lump in the abdomen, neck, or chest, or a painless bluish lump under the skin.

<span class="mw-page-title-main">Neurofibromatosis type II</span> Type of neurofibromatosis disease

Neurofibromatosis type II is a genetic condition that may be inherited or may arise spontaneously, and causes benign tumors of the brain, spinal cord, and peripheral nerves. The types of tumors frequently associated with NF2 include vestibular schwannomas, meningiomas, and ependymomas. The main manifestation of the condition is the development of bilateral benign brain tumors in the nerve sheath of the cranial nerve VIII, which is the "auditory-vestibular nerve" that transmits sensory information from the inner ear to the brain. Besides, other benign brain and spinal tumors occur. Symptoms depend on the presence, localisation and growth of the tumor(s), in which multiple cranial nerves can be involved. Many people with this condition also experience vision problems. Neurofibromatosis type II is caused by mutations of the "Merlin" gene, which seems to influence the form and movement of cells. The principal treatments consist of neurosurgical removal of the tumors and surgical treatment of the eye lesions. Historically the underlying disorder has not had any therapy due to the cell function caused by the genetic mutation.

<span class="mw-page-title-main">Uveal melanoma</span> Type of eye cancer

Uveal melanoma is a type of eye cancer in the uvea of the eye. It is traditionally classed as originating in the iris, choroid, and ciliary body, but can also be divided into class I and class II. Symptoms include blurred vision, loss of vision or photopsia, but there may be no symptoms.

<span class="mw-page-title-main">Medulloblastoma</span> Most common type of primary brain cancer in children

Medulloblastoma is a common type of primary brain cancer in children. It originates in the part of the brain that is towards the back and the bottom, on the floor of the skull, in the cerebellum, or posterior fossa.

<span class="mw-page-title-main">Undifferentiated pleomorphic sarcoma</span> Medical condition

Undifferentiated pleomorphic sarcoma (UPS), also termed pleomorphic myofibrosarcoma, high-grade myofibroblastic sarcoma, and high-grade myofibrosarcoma, is characterized by the World Health Organization (WHO), 2020, as a rare, poorly differentiated neoplasm, i.e. an abnormal growth of cells that have an unclear identity and/or cell of origin. WHO classified it as one of the undifferentiated/unclassified sarcomas in the category of tumors of uncertain differentiation. Sarcomas are cancers known or thought to derive from mesenchymal stem cells that typically develop in bone, muscle, fat, blood vessels, lymphatic vessels, tendons, and ligaments. More than 70 sarcoma subtypes have been described. The UPS subtype of these sarcomas consists of tumor cells that are poorly differentiated and may appear as spindle-shaped cells, histiocytes, and giant cells. UPS is considered a diagnosis that defies formal sub-classification after thorough histologic, immunohistochemical, and ultrastructural examinations fail to identify the type of cells involved.

<span class="mw-page-title-main">Atypical teratoid rhabdoid tumor</span> Medical condition

An atypical teratoid rhabdoid tumor (AT/RT) is a rare tumor usually diagnosed in childhood. Although usually a brain tumor, AT/RT can occur anywhere in the central nervous system (CNS), including the spinal cord. About 60% will be in the posterior cranial fossa. One review estimated 52% in the posterior fossa, 39% are supratentorial primitive neuroectodermal tumors (sPNET), 5% are in the pineal, 2% are spinal, and 2% are multifocal.

<span class="mw-page-title-main">Telomerase reverse transcriptase</span> Catalytic subunit of the enzyme telomerase

Telomerase reverse transcriptase is a catalytic subunit of the enzyme telomerase, which, together with the telomerase RNA component (TERC), comprises the most important unit of the telomerase complex.

<span class="mw-page-title-main">PINX1</span> Protein-coding gene in the species Homo sapiens

PIN2/TERF1-interacting telomerase inhibitor 1, also known as PINX1, is a human gene. PINX1 is also known as PIN2 interacting protein 1. PINX1 is a telomerase inhibitor and a possible tumor suppressor.

Virtual karyotype is the digital information reflecting a karyotype, resulting from the analysis of short sequences of DNA from specific loci all over the genome, which are isolated and enumerated. It detects genomic copy number variations at a higher resolution for level than conventional karyotyping or chromosome-based comparative genomic hybridization (CGH). The main methods used for creating virtual karyotypes are array-comparative genomic hybridization and SNP arrays.

<span class="mw-page-title-main">Inflammatory myofibroblastic tumour</span> Medical condition

Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm of the mesodermal cells that form the connective tissues which support virtually all of the organs and tissues of the body. IMT was formerly termed inflammatory pseudotumor. Currently, however, inflammatory pseudotumor designates a large and heterogeneous group of soft tissue tumors that includes inflammatory myofibroblastic tumor, plasma cell granuloma, xanthomatous pseudotumor, solitary mast cell granuloma, inflammatory fibrosarcoma, pseudosarcomatous myofibroblastic proliferation, myofibroblastoma, inflammatory myofibrohistiocytic proliferation, and other tumors that develop from connective tissue cells. Inflammatory pseudotumour is a generic term applied to various neoplastic and non-neoplastic tissue lesions which share a common microscopic appearance consisting of spindle cells and a prominent presence of the white blood cells that populate chronic or, less commonly, acute inflamed tissues.

<span class="mw-page-title-main">Cancer biomarker</span> Substance or process that is indicative of the presence of cancer in the body

A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected biofluids like blood or serum.

Myxofibrosarcoma (MFS), although a rare type of tumor, is one of the most common soft tissue sarcomas, i.e. cancerous tumors, that develop in the soft tissues of elderly individuals. Initially considered to be a type of histiocytoma termed fibrous histiocytoma or myxoid variant of malignant fibrous histiocytoma, Angervall et al. termed this tumor myxofibrosarcoma in 1977. In 2020, the World Health Organization reclassified MFS as a separate and distinct tumor in the category of malignant fibroblastic and myofibroblastic tumors.

References

  1. 1 2 3 4 5 Taylor, MD; Poppleton, H; Fuller, C; Su, X; Liu, Y; Jensen, P; Magdaleno, S; Dalton, J; et al. (2005). "Radial glia cells are candidate stem cells of ependymoma". Cancer Cell. 8 (4): 323–35. doi: 10.1016/j.ccr.2005.09.001 . PMID   16226707.
  2. ↑ Hartfuss, E; Galli, R; Heins, N; Götz, M (2001). "Characterization of CNS precursor subtypes and radial glia". Developmental Biology. 229 (1): 15–30. doi: 10.1006/dbio.2000.9962 . PMID   11133151.
  3. 1 2 3 De Bont, JM; Packer, RJ; Michiels, EM; Den Boer, ML; Pieters, R (2008). "Biological background of pediatric medulloblastoma and ependymoma: A review from a translational research perspective". Neuro-Oncology. 10 (6): 1040–60. doi:10.1215/15228517-2008-059. PMC   2719002 . PMID   18676356.
  4. 1 2 Rubio, MP; Correa, KM; Ramesh, V; MacCollin, MM; Jacoby, LB; Von Deimling, A; Gusella, JF; Louis, DN (1994). "Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas". Cancer Research. 54 (1): 45–7. PMID   8261460.
  5. ↑ Birch, BD; Johnson, JP; Parsa, A; Desai, RD; Yoon, JT; Lycette, CA; Li, YM; Bruce, JN (1996). "Frequent type 2 neurofibromatosis gene transcript mutations in sporadic intramedullary spinal cord ependymomas". Neurosurgery. 39 (1): 135–40. doi:10.1097/00006123-199607000-00026. PMID   8805149.
  6. ↑ Ebert, C; Von Haken, M; Meyer-Puttlitz, B; Wiestler, OD; Reifenberger, G; Pietsch, T; Von Deimling, A (1999). "Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas". The American Journal of Pathology. 155 (2): 627–32. doi:10.1016/S0002-9440(10)65158-9. PMC   1866851 . PMID   10433955.
  7. ↑ Buccoliero, AM; Castiglione, F; Degl'innocenti, DR; Sardi, I; Genitori, L; Taddei, GL (2010). "Merlin expression in pediatric anaplastic ependymomas real time PCR study" (PDF). Fetal and Pediatric Pathology. 29 (4): 245–54. doi:10.3109/15513811003789644. hdl: 2158/795259 . PMID   20594149. S2CID   40842469.
  8. 1 2 Gilbertson, RJ; Bentley, L; Hernan, R; Junttila, TT; Frank, AJ; Haapasalo, H; Connelly, M; Wetmore, C; et al. (2002). "ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease". Clinical Cancer Research. 8 (10): 3054–64. PMID   12374672.
  9. 1 2 3 Mendrzyk, F; Korshunov, A; Benner, A; Toedt, G; Pfister, S; Radlwimmer, B; Lichter, P (2006). "Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma". Clinical Cancer Research. 12 (7 Pt 1): 2070–9. doi: 10.1158/1078-0432.CCR-05-2363 . PMID   16609018. S2CID   12006455.
  10. ↑ Rushing, EJ; Yashima, K; Brown, DF; White Cl, 3rd; Shay, JW; Risser, RC; Gazdar, AF (1997). "Expression of telomerase RNA component correlates with the MIB-1 proliferation index in ependymomas". Journal of Neuropathology and Experimental Neurology. 56 (10): 1142–6. doi: 10.1097/00005072-199710000-00008 . PMID   9329458. S2CID   36687980.
  11. ↑ Peyre, M; Commo, F; Dantas-Barbosa, C; Andreiuolo, F; Puget, S; Lacroix, L; Drusch, F; Scott, V; et al. (2010). Jones, Chris (ed.). "Portrait of ependymoma recurrence in children: Biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis". PLOS ONE. 5 (9): e12932. Bibcode:2010PLoSO...512932P. doi: 10.1371/journal.pone.0012932 . PMC   2945762 . PMID   20885975.
  12. 1 2 3 Puputti, M; Tynninen, O; Pernilä, P; Salmi, M; Jalkanen, S; Paetau, A; Sihto, H; Joensuu, H (2010). "Expression of KIT receptor tyrosine kinase in endothelial cells of juvenile brain tumors". Brain Pathology (Zurich, Switzerland). 20 (4): 763–70. doi:10.1111/j.1750-3639.2009.00357.x. PMC   2901521 . PMID   20030644.
  13. 1 2 3 Kilday, JP; Rahman, R; Dyer, S; Ridley, L; Lowe, J; Coyle, B; Grundy, R (2009). "Pediatric ependymoma: Biological perspectives". Molecular Cancer Research. 7 (6): 765–86. doi: 10.1158/1541-7786.MCR-08-0584 . PMID   19531565. S2CID   2409031.
  14. 1 2 Mazewski, C; Soukup, S; Ballard, E; Gotwals, B; Lampkin, B (1999). "Karyotype studies in 18 ependymomas with literature review of 107 cases". Cancer Genetics and Cytogenetics. 113 (1): 1–8. doi:10.1016/S0165-4608(99)00046-1. PMID   10459338.
  15. ↑ Reardon, DA; Entrekin, RE; Sublett, J; Ragsdale, S; Li, H; Boyett, J; Kepner, JL; Look, AT (1999). "Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma". Genes, Chromosomes & Cancer. 24 (3): 230–7. doi:10.1002/(SICI)1098-2264(199903)24:3<230::AID-GCC8>3.0.CO;2-C. PMID   10451703.
  16. ↑ Ward, S; Harding, B; Wilkins, P; Harkness, W; Hayward, R; Darling, JL; Thomas, DG; Warr, T (2001). "Gain of 1q and loss of 22 are the most common changes detected by comparative genomic hybridisation in paediatric ependymoma". Genes, Chromosomes & Cancer. 32 (1): 59–66. doi:10.1002/gcc.1167. hdl: 2436/16712 . PMID   11477662. S2CID   10805975.
  17. ↑ Nijssen, PC; Deprez, RH; Tijssen, CC; Hagemeijer, A; Arnoldus, EP; Teepen, JL; Holl, R; Niermeyer, MF (1994). "Familial anaplastic ependymoma: Evidence of loss of chromosome 22 in tumour cells". Journal of Neurology, Neurosurgery, and Psychiatry. 57 (10): 1245–8. doi:10.1136/jnnp.57.10.1245. PMC   485495 . PMID   7931388.
  18. 1 2 Von Haken, MS; White, EC; Daneshvar-Shyesther, L; Sih, S; Choi, E; Kalra, R; Cogen, PH (1996). "Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas". Genes, Chromosomes & Cancer. 17 (1): 37–44. doi:10.1002/(SICI)1098-2264(199609)17:1<37::AID-GCC6>3.0.CO;2-3. PMID   8889505.
  19. ↑ Kramer, DL; Parmiter, AH; Rorke, LB; Sutton, LN; Biegel, JA (1998). "Molecular cytogenetic studies of pediatric ependymomas". Journal of Neuro-Oncology. 37 (1): 25–33. doi:10.1023/A:1005925613992. PMID   9525835. S2CID   2339505.
  20. ↑ Slavc, I; MacCollin, MM; Dunn, M; Jones, S; Sutton, L; Gusella, JF; Biegel, JA (1995). "Exon scanning for mutations of the NF2 gene in pediatric ependymomas, rhabdoid tumors and meningiomas". International Journal of Cancer. 64 (4): 243–7. doi:10.1002/ijc.2910640406. PMID   7657387. S2CID   26113908.
  21. ↑ Suarez-Merino, B; Hubank, M; Revesz, T; Harkness, W; Hayward, R; Thompson, D; Darling, JL; Thomas, DG; Warr, TJ (2005). "Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3". Neuro-Oncology. 7 (1): 20–31. doi:10.1215/S1152851704000596). PMC   1871622 . PMID   15701279.
  22. 1 2 3 Puget, S; Grill, J; Valent, A; Bieche, I; Dantas-Barbosa, C; Kauffmann, A; Dessen, P; Lacroix, L; et al. (2009). "Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas". Journal of Clinical Oncology. 27 (11): 1884–92. doi: 10.1200/JCO.2007.15.4195 . PMID   19289631.
  23. ↑ Urioste, M; Martínez-Ramírez, A; Cigudosa, JC; Colmenero, I; Madero, L; Robledo, M; Martínez-Delgado, B; Benítez, J (2002). "Complex cytogenetic abnormalities including telomeric associations and MEN1 mutation in a pediatric ependymoma". Cancer Genetics and Cytogenetics. 138 (2): 107–10. doi:10.1016/S0165-4608(01)00532-5. PMID   12505253.
  24. 1 2 3 Snuderl, M; Chi, SN; De Santis, SM; Stemmer-Rachamimov, AO; Betensky, RA; De Girolami, U; Kieran, MW (2008). "Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas". Journal of Neuropathology and Experimental Neurology. 67 (9): 911–20. doi:10.1097/NEN.0b013e318184f413. PMC   2686114 . PMID   18716553.
  25. ↑ Karakoula, K; Suarez-Merino, B; Ward, S; Phipps, KP; Harkness, W; Hayward, R; Thompson, D; Jacques, TS; et al. (2008). "Real-time quantitative PCR analysis of pediatric ependymomas identifies novel candidate genes including TPR at 1q25 and CHIBBY at 22q12-q13". Genes, Chromosomes & Cancer. 47 (11): 1005–22. doi:10.1002/gcc.20607. PMID   18663750. S2CID   39179289.
  26. ↑ Rand, V; Prebble, E; Ridley, L; Howard, M; Wei, W; Brundler, MA; Fee, BE; Riggins, GJ; et al. (2008). "Investigation of chromosome 1q reveals differential expression of members of the S100 family in clinical subgroups of intracranial paediatric ependymoma". British Journal of Cancer. 99 (7): 1136–43. doi:10.1038/sj.bjc.6604651. PMC   2567087 . PMID   18781180.
  27. ↑ Fink, KL; Rushing, EJ; Schold Jr, SC; Nisen, PD (1996). "Infrequency of p53 gene mutations in ependymomas". Journal of Neuro-Oncology. 27 (2): 111–5. doi:10.1007/bf00177473. PMID   8699232. S2CID   35235002.
  28. ↑ Gaspar, N; Grill, J; Geoerger, B; Lellouch-Tubiana, A; Michalowski, MB; Vassal, G (2006). "P53 Pathway dysfunction in primary childhood ependymomas". Pediatric Blood & Cancer. 46 (5): 604–13. doi:10.1002/pbc.20532. PMID   16086408. S2CID   25126455.
  29. ↑ Sharma, MC; Ghara, N; Jain, D; Sarkar, C; Singh, M; Mehta, VS (2009). "A study of proliferative markers and tumor suppressor gene proteins in different grades of ependymomas". Neuropathology. 29 (2): 148–55. doi: 10.1111/j.1440-1789.2008.00962.x . PMID   18721229. S2CID   36816458.
  30. ↑ Suzuki, SO; Iwaki, T (2000). "Amplification and overexpression of mdm2 gene in ependymomas". Modern Pathology. 13 (5): 548–53. doi: 10.1038/modpathol.3880095 . PMID   10824927. S2CID   23561451.
  31. ↑ De Bont, JM; Van Doorn, J; Reddingius, RE; Graat, GH; Passier, MM; Den Boer, ML; Pieters, R (2008). "Various components of the insulin-like growth factor system in tumor tissue, cerebrospinal fluid and peripheral blood of pediatric medulloblastoma and ependymoma patients". International Journal of Cancer. 123 (3): 594–600. doi: 10.1002/ijc.23558 . PMID   18478565. S2CID   24781824.
  32. 1 2 3 Ridley, L; Rahman, R; Brundler, MA; Ellison, D; Lowe, J; Robson, K; Prebble, E; Luckett, I; et al. (2008). "Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma". Neuro-Oncology. 10 (5): 675–89. doi:10.1215/15228517-2008-036. PMC   2666244 . PMID   18701711.
  33. ↑ Piepmeier, JM (1996). "Tumors and approaches to the lateral ventricles. Introduction and overview". Journal of Neuro-Oncology. 30 (3): 267–74. doi:10.1007/bf00177278. PMID   8943102. S2CID   11019256.
  34. ↑ Shemie, S; Jay, V; Rutka, J; Armstrong, D (1997). "Acute obstructive hydrocephalus and sudden death in children". Annals of Emergency Medicine. 29 (4): 524–8. doi:10.1016/S0196-0644(97)70227-0. PMID   9095015.
  35. 1 2 Tamburrini, G; D'ercole, M; Pettorini, BL; Caldarelli, M; Massimi, L; Di Rocco, C (2009). "Survival following treatment for intracranial ependymoma: A review". Child's Nervous System. 25 (10): 1303–12. doi:10.1007/s00381-009-0874-y. PMID   19387655. S2CID   24939807.
  36. ↑ Peretti-Viton, P; Perez Castillo, AM; Martini, P; Margain, D; Murayama, N (1991). "Supratentorial ependymomas. Neuroradiological study". Journal of Neuroradiology. Journal de Neuroradiologie. 18 (2): 201–9. PMID   1919685.
  37. ↑ Godfraind, C (2009). "Classification and controversies in pathology of ependymomas". Child's Nervous System. 25 (10): 1185–93. doi:10.1007/s00381-008-0804-4. PMID   19212775. S2CID   25100075.
  38. ↑ Louis, DN; Ohgaki, H; Wiestler, OD; Cavenee, WK; Burger, PC; Jouvet, A; Scheithauer, BW; Kleihues, P (2007). "The 2007 WHO classification of tumours of the central nervous system". Acta Neuropathologica. 114 (2): 97–109. doi:10.1007/s00401-007-0243-4. PMC   1929165 . PMID   17618441.
  39. ↑ Pezzolo, A; Capra, V; Raso, A; Morandi, F; Parodi, F; Gambini, C; Nozza, P; Giangaspero, F; et al. (2008). "Identification of novel chromosomal abnormalities and prognostic cytogenetics markers in intracranial pediatric ependymoma". Cancer Letters. 261 (2): 235–43. doi:10.1016/j.canlet.2007.11.021. PMID   18179864.
  40. ↑ Takei, H; Bhattacharjee, MB; Rivera, A; Dancer, Y; Powell, SZ (2007). "New immunohistochemical markers in the evaluation of central nervous system tumors: A review of 7 selected adult and pediatric brain tumors". Archives of Pathology & Laboratory Medicine. 131 (2): 234–41. doi:10.5858/2007-131-234-NIMITE. ISSN   1543-2165. PMID   17284108.
  41. ↑ Terterov, S; Krieger, MD; Bowen, I; McComb, JG (2010). "Evaluation of intracranial cerebrospinal fluid cytology in staging pediatric medulloblastomas, supratentorial primitive neuroectodermal tumors, and ependymomas". Journal of Neurosurgery. Pediatrics. 6 (2): 131–6. doi:10.3171/2010.5.PEDS09333. PMID   20672933. S2CID   32766866.
  42. ↑ Borges, CB; Bernardes, ES; Latorraca, EF; Becker, AP; Neder, L; Chammas, R; Roque-Barreira, MC; Machado, HR; De Oliveira, RS (2011). "Galectin-3 expression: A useful tool in the differential diagnosis of posterior fossa tumors in children". Child's Nervous System. 27 (2): 253–7. doi:10.1007/s00381-010-1262-3. PMID   20711594. S2CID   41243460.
  43. ↑ Barton, VN; Donson, AM; Kleinschmidt-Demasters, BK; Birks, DK; Handler, MH; Foreman, NK (2010). "Unique molecular characteristics of pediatric myxopapillary ependymoma". Brain Pathology (Zurich, Switzerland). 20 (3): 560–70. doi:10.1111/j.1750-3639.2009.00333.x. PMC   2871180 . PMID   19793339.
  44. ↑ De Bont, JM; Kros, JM; Passier, MM; Reddingius, RE; Sillevis Smitt, PA; Luider, TM; Den Boer, ML; Pieters, R (2008). "Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis". Neuro-Oncology. 10 (5): 648–60. doi:10.1215/15228517-2008-032. PMC   2666242 . PMID   18577562.
  45. ↑ Martínez León, MI; Vidal Denis, M; Weil Lara, B (2011). "Magnetic resonance imaging of infratentorial anaplastic ependymoma in children". Radiología. 54 (1): 59–64. doi:10.1016/j.rx.2011.01.005. PMID   21530988.
  46. ↑ Sala, F; Talacchi, A; Mazza, C; Prisco, R; Ghimenton, C; Bricolo, A (1998). "Prognostic factors in childhood intracranial ependymomas: The role of age and tumor location". Pediatric Neurosurgery. 28 (3): 135–42. doi:10.1159/000028637. PMID   9705591. S2CID   46820616.
  47. ↑ Tabori, U; Ma, J; Carter, M; Zielenska, M; Rutka, J; Bouffet, E; Bartels, U; Malkin, D; Hawkins, C (2006). "Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma". Journal of Clinical Oncology. 24 (10): 1522–8. doi: 10.1200/JCO.2005.04.2127 . PMID   16575002.
  48. ↑ Monoranu, CM; Huang, B; Zangen, IL; Rutkowski, S; Vince, GH; Gerber, NU; Puppe, B; Roggendorf, W (2008). "Correlation between 6q25.3 deletion status and survival in pediatric intracranial ependymomas". Cancer Genetics and Cytogenetics. 182 (1): 18–26. doi:10.1016/j.cancergencyto.2007.12.008. PMID   18328946.
  49. ↑ Wright, KD; Gajjar, A (2009). "New chemotherapy strategies and biological agents in the treatment of childhood ependymoma". Child's Nervous System. 25 (10): 1275–82. doi:10.1007/s00381-009-0809-7. PMC   2738756 . PMID   19212772.
  50. ↑ Shim, KW; Kim, DS; Choi, JU (2009). "The history of ependymoma management". Child's Nervous System. 25 (10): 1167–83. doi:10.1007/s00381-009-0900-0. PMID   19458954. S2CID   1168021.
  51. ↑ Little, AS; Sheean, T; Manoharan, R; Darbar, A; Teo, C (2009). "The management of completely resected childhood intracranial ependymoma: The argument for observation only". Child's Nervous System. 25 (3): 281–4. doi:10.1007/s00381-008-0799-x. PMID   19153750. S2CID   10791698.
  52. ↑ Goldwein, JW; Leahy, JM; Packer, RJ; Sutton, LN; Curran, WJ; Rorke, LB; Schut, L; Littman, PS; D'angio, GJ (1990). "Intracranial ependymomas in children". International Journal of Radiation Oncology, Biology, Physics. 19 (6): 1497–502. doi:10.1016/0360-3016(90)90362-N. PMID   2262372.
  53. ↑ Tihan, T; Zhou, T; Holmes, E; Burger, PC; Ozuysal, S; Rushing, EJ (2008). "The prognostic value of histological grading of posterior fossa ependymomas in children: A Children's Oncology Group study and a review of prognostic factors". Modern Pathology. 21 (2): 165–77. doi: 10.1038/modpathol.3800999 . PMID   18084249. S2CID   12129583.
  54. ↑ Wong, VC; Morrison, A; Tabori, U; Hawkins, CE (2010). "Telomerase inhibition as a novel therapy for pediatric ependymoma". Brain Pathology (Zurich, Switzerland). 20 (4): 780–6. doi:10.1111/j.1750-3639.2010.00372.x. PMC   8094828 . PMID   20184588. S2CID   12167031.
  55. ↑ Bobola, MS; Jankowski, P; Gross, ME; Schwartz, J; Finn, LS; Blank, A; Ellenbogen, RG; Silber, JR (2011). "Apurinic/apyrimidinic endonuclease is inversely associated with response to radiotherapy in pediatric ependymoma". International Journal of Cancer. 129 (10): 2370–2379. doi:10.1002/ijc.25900. PMC   3285472 . PMID   21207372.
  56. ↑ McGuire, CS; Sainani, KL; Fisher, PG (2009). "Both location and age predict survival in ependymoma: A SEER study". Pediatric Blood & Cancer. 52 (1): 65–9. doi: 10.1002/pbc.21806 . PMID   19006249. S2CID   39107535.
  57. ↑ Kano, H; Yang, HC; Kondziolka, D; Niranjan, A; Arai, Y; Flickinger, JC; Lunsford, LD (2010). "Stereotactic radiosurgery for pediatric recurrent intracranial ependymomas". Journal of Neurosurgery. Pediatrics. 6 (5): 417–23. doi:10.3171/2010.8.PEDS10252. PMID   21039163. S2CID   21039435.
  58. ↑ Kumar, R; Singhal, N; Jaiswal, SK; Mahapatra, AK (2007). "Recurrence in supratentorial anaplastic ependymoma". Pediatric Neurosurgery. 43 (5): 364–8. doi:10.1159/000106384. PMID   17786000. S2CID   44479846.
  59. ↑ U-King-Im, JM; Taylor, MD; Raybaud, C (2010). "Posterior fossa ependymomas: New radiological classification with surgical correlation". Child's Nervous System. 26 (12): 1765–72. doi:10.1007/s00381-010-1251-6. PMID   20680298. S2CID   36988633.
  60. 1 2 Shimoji, K; Miyajima, M; Karagiozov, K; Yatomi, K; Matsushima, T; Arai, H (2009). "Surgical considerations in fourth ventricular ependymoma with the transcerebellomedullary fissure approach in focus". Child's Nervous System. 25 (10): 1221–8. doi:10.1007/s00381-009-0835-5. PMID   19360422. S2CID   11225552.
  61. ↑ Good, CD; Wade, AM; Hayward, RD; Phipps, KP; Michalski, AJ; Harkness, WF; Chong, WK (2001). "Surveillance neuroimaging in childhood intracranial ependymoma: How effective, how often, and for how long?". Journal of Neurosurgery. 94 (1): 27–32. doi:10.3171/jns.2001.94.1.0027. PMID   11147894.
  62. 1 2 Tabori, U; Wong, V; Ma, J; Shago, M; Alon, N; Rutka, J; Bouffet, E; Bartels, U; et al. (2008). "Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma". British Journal of Cancer. 99 (7): 1129–35. doi:10.1038/sj.bjc.6604652. PMC   2567068 . PMID   18797459.
  63. 1 2 Sanford, RA; Gajjar, A (1997). "Ependymomas". Clinical Neurosurgery. 44: 559–70. PMID   10080027.
  64. ↑ Agaoglu, FY; Ayan, I; Dizdar, Y; Kebudi, R; Gorgun, O; Darendeliler, E (2005). "Ependymal tumors in childhood". Pediatric Blood & Cancer. 45 (3): 298–303. doi:10.1002/pbc.20212. PMID   15770637. S2CID   45562929.
  65. ↑ Castelo-Branco, P; Zhang, C; Lipman, T; Fujitani, M; Hansford, L; Clarke, I; Harley, CB; Tressler, R; et al. (2011). "Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition". Clinical Cancer Research. 17 (1): 111–21. doi: 10.1158/1078-0432.CCR-10-2075 . PMID   21208905. S2CID   727839.
  66. ↑ Levisohn, L; Cronin-Golomb, A; Schmahmann, JD (2000). "Neuropsychological consequences of cerebellar tumour resection in children: Cerebellar cognitive affective syndrome in a paediatric population". Brain. 123 (5): 1041–50. doi: 10.1093/brain/123.5.1041 . PMID   10775548.
  67. ↑ Winick, N (2011). "Neurocognitive outcome in survivors of pediatric cancer". Current Opinion in Pediatrics. 23 (1): 27–33. doi:10.1097/MOP.0b013e32834255e9. PMID   21157347. S2CID   205834954.
  68. ↑ Mostoufi-Moab, S; Grimberg, A (2010). "Pediatric brain tumor treatment: Growth consequences and their management". Pediatric Endocrinology Reviews. 8 (1): 6–17. PMC   4148717 . PMID   21037539.
  69. ↑ Goldsby, R; Chen, Y; Raber, S; Li, L; Diefenbach, K; Shnorhavorian, M; Kadan-Lottick, N; Kastrinos, F; et al. (2011). "Survivors of childhood cancer have increased risk of gastrointestinal complications later in life". Gastroenterology. 140 (5): 1464–71.e1. doi:10.1053/j.gastro.2011.01.049. PMC   3081911 . PMID   21315721.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.